NCT05931328招募中2 期
A Single-arm, Prospective, Multicenter Clinical Trial of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma.
The First Affiliated Hospital with Nanjing Medical University1 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2022年10月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Adverse event rate
研究概览
简要总结
The aim of this study is to evaluate the efficacy and safety of the combination of thiotepa and pomalidomide in the treatment of relapsed/refractory (R/R) primary central nervous system lymphoma (PCNSL).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically confirmed PCNSL, diagnosed according to the 2016 WHO diagnostic criteria. Previously treated with at least one course of chemotherapy, with disease progression or recurrence.
- •Aged 18 to 75 years old; ECOG PS score of 0 to 4 points; Expected survival time of more than 3 months; A whole-body PET/CT and head MR (plain scan + enhancement) performed within 28 days before study enrollment should show at least one measurable lesion in two perpendicular directions (based on the 2014 Lugano criteria), or abnormal findings in cerebrospinal fluid examination (including cerebrospinal fluid cells, NGS), or ocular examination confirming lesions in the retina or vitreous body;
- •Adequate organ function, defined as follows:
- •Liver function: serum total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; Renal function: serum creatinine (Cr) ≤ 1 × ULN or creatinine clearance rate (CCR) ≥ 90 mL/min; Cardiac function: cardiac function grade of III or less (NYHA standard); echocardiography shows an ejection fraction of ≥50%; Coagulation function: international normalized ratio (INR) ≤ 1.5 × ULN, activated partial thromboplastin time (APTT) ≤ 10s, and prothrombin time (PT) ≤ 3s; Thyroid function: baseline thyroid-stimulating hormone (TSH) level is normal or baseline TSH is abnormal, but T3/T4 is normal and there are no symptoms; Women of childbearing age must take contraceptive measures or undergo a pregnancy test with a negative result before enrollment, and take contraceptive measures during the trial and within 90 days after the last dose of the drug; for men, contraceptive measures must be taken during the trial and within 90 days after the last dose of the drug, or they must have undergone surgical sterilization; The subject voluntarily agrees to participate in the study, signs an informed consent form, has good compliance, and cooperates with follow-up.
排除标准
- •Pregnant or lactating women; Patients with involvement of sites other than the central nervous system; Patients with bone marrow failure, specifically defined as absolute neutrophil count (ANC) <1.5 x 109/L, platelets <75 x 109/L, and hemoglobin <70 g/L;
- •Patients diagnosed with malignant tumors other than lymphoma or currently undergoing treatment, with the following exceptions:
- •Patients who have received curative treatment and have not had any known active malignant tumors for ≥5 years prior to enrollment; ② Patients with adequately treated basal cell carcinoma of the skin without evidence of disease (excluding melanoma); ③ Patients with adequately treated cervical intraepithelial neoplasia without evidence of disease.
- •Known allergy to any component of the investigational drug; Patients who have undergone allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; Patients who may receive other systemic anti-tumor therapy during the study period; Patients with human immunodeficiency virus (HIV) antibodies, active hepatitis, or other uncontrolled infectious diseases; Patients with a history of clear neurological or psychiatric disorders; Patients who may interfere with the participation of the subject in the study or the evaluation of study results due to drug abuse, medical, psychological or social conditions; Patients deemed unsuitable for enrollment by the investigator.
研究组 & 干预措施
thiotepa+pomalidomide
Experimental
thiotepa combined with pomalidomide: thiotepa 30mg/m2,intravenously guttae, on day 1; pomalidomide 12mg orally daily for 2 weeks. A chemotherapy cycle lasts for 3 weeks.
干预措施: thiotepa combined with pomalidomide (Drug)
结局指标
主要结局
Adverse event rate
时间窗: Baseline up to 3 years.
The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).
Overall Response Rate (ORR)
时间窗: Baseline up to 2 years.
The proportion of subjects who achieves a best overall response of CR or PR.
次要结局
- Duration of Response（DOR）(Baseline up to 2 years.)
- 2-year Overall Survival（OS）rate(Baseline up to 3 years.)
- 2-year Progression-free Survival (PFS) rate(Baseline up to 2 years.)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal MetastasisLeptomeningeal Metastasis of Breast CancerNCT06543992The First Affiliated Hospital with Nanjing Medical University22
招募中
2 期
TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With AutoantibodiesImmune Thrombocytopenia (ITP)AutoantibodiesEvan SyndromeConnective Tissue DiseasesNCT04915482Institute of Hematology & Blood Diseases Hospital, China94
已完成
2 期
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.Epilepsies, PartialSeizuresEpilepsyNCT00236691Johnson & Johnson Pharmaceutical Research & Development, L.L.C.188
Unknown
2 期
Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell CarcinomaLocally Advanced Esophageal Squamous Cell CarcinomaNCT04888403The First Affiliated Hospital of Zhengzhou University45
招募中
不适用
A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/EzetimibPrimary HypercholesterolemiaMixed DyslipidemiaNCT06314919Boryung Pharmaceutical Co., Ltd8,606